NCT07737249尚未招募2 期
A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Golidocitinib in Rapidly Progressive Interstitial Lung Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Rate of change in absolute forced vital capacity (FVC) in milliliters (mL) within 12 weeks
研究概览
简要总结
The goal of this clinical trial is to learn whether adding the JAK inhibitor golidocitinib to standard corticosteroid therapy works to treat rapidly progressive interstitial lung disease (RP-ILD) in patients with acute worsening. It will also learn about its safety compared to standard treatment without JAK inhibitors (i.e., corticosteroids plus other immunosuppressants such as mycophenolate mofetil, tacrolimus, cyclophosphamide, or biologics).
The main questions it aims to answer are:
- How much does the addition of golidocitinib improve lung function, measured by the absolute change in FVC (mL), after 12 weeks of treatment?
- How does it compare to standard therapy in terms of changes in FVC% predicted, oxygenation index, chest CT score, need for invasive respiratory support, all-cause mortality, relapse rate, and incidence of opportunistic infections?
Researchers will compare the golidocitinib group (golidocitinib 150 mg once daily plus corticosteroids) to the control group (corticosteroids plus non-JAK inhibitor immunosuppressants). All patients receive high-dose corticosteroids (prednisone equivalent ≥1 mg/kg/day) with a tapering regimen.
Participants will:
- Receive either golidocitinib plus corticosteroids or control treatment for 12 weeks
- Visit the clinic for check-ups, blood tests, and lung function tests at weeks 1, 2, 4, 6-8, and 12
- Have chest high-resolution CT scans at weeks 2, 4-6, and 12 to monitor disease progression
- Be monitored for adverse events and efficacy outcomes throughout the 12-week period
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Meet the diagnostic criteria for rapidly progressive interstitial lung disease (RP-ILD) and require treatment with corticosteroids and immunosuppressants, defined as: Acute worsening of cough and dyspnea occurring within 1 month; Chest CT showing ILD manifestations with new or worsening exudative lesions (ground-glass opacities and/or consolidation); Presence of respiratory failure (PaO₂ < 60 mmHg at rest without oxygen supplementation, or SpO₂ < 90% on room air), or significant worsening of hypoxemia (a decrease in PaO₂ of ≥ 10 mmHg), or a clear decline in two recent pulmonary function tests: a decrease in FVC % predicted of ≥ 10% and/or a decrease in DLCO % predicted of ≥ 15% accompanied by a decline in FVC; Exclusion of heart failure or fluid overload, pulmonary infectious diseases, and pulmonary embolism
- •No prior treatment with JAK inhibitors
- •Able to comply with scheduled follow-up visits
- •Patient and family members understand the study protocol, are willing to participate, and are able to provide written informed consent.
排除标准
- •The patient or family members are unable to understand the conditions and objectives of this study, or are unable to provide informed consent
- •Subjects who are unable to comply with the follow-up schedule as required by the protocol, including those who cannot cooperate with pulmonary function testing
- •Presence of other severe diseases that, in the investigator's opinion, may affect patient safety or compliance
- •Any significant clinical or laboratory abnormalities that, in the investigator's opinion, may affect the safety evaluation
- •Oxygenation index ≤ 100, and/or requirement for invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) support
- •Pregnant or lactating women, as well as patients who are unable to use effective contraception during the study period and within 3 months after the end of the study
- •Presence of contraindications to golidocitinib administration, including a history of allergy to relevant drugs, or presence of active and uncontrolled infections, such as evidence of HIV, HBV (HBsAg-positive, HBV-DNA-positive or ≥ 1000 copies/mL), HCV (anti-HCV antibody-positive or HCV-RNA-positive), or any symptomatic bacterial, viral, parasitic, or fungal infection requiring treatment
- •Need for concomitant use of acetaminophen or propacetamol, or preparations containing these ingredients
结局指标
主要结局
Rate of change in absolute forced vital capacity (FVC) in milliliters (mL) within 12 weeks
时间窗: Week 12
次要结局
- Change in chest CT score within 12 weeks(Week 12)
- Absolute change in FVC % predicted within 12 weeks(Week 12)
- Percent change in FVC % predicted within 12 weeks(Week 12)
- Absolute change in oxygenation index within 12 weeks(Week 12)
- Proportion of patients requiring invasive respiratory support within 12 weeks(Week 12)
- All-cause mortality within 12 weeks(Week 12)
- Relapse rate within 12 weeks(Week 12)
- Incidence of opportunistic infections within 12 weeks(Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaMycosis Fungoides/Sezary SyndromeT-cell Large Granular Lymphocytic LeukemiaNCT07682792Washington University School of Medicine24
尚未招募
2 期
Golidocitinib Combined With GemOx in RR PTCLNCT07279584Ruijin Hospital31
尚未招募
3 期
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaMaintenance Treatment of Peripheral T-cell LymphomaNCT07300514Fudan University136
招募中
1 期
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)T-cell LymphomasNCT07496229Dizal Pharmaceuticals165
招募中
2 期
Prospective Single-Arm Clinical Trial of GO Regimen for HLH.NCT07339345Beijing Friendship Hospital28